Evidence map›Paper›PMID 36394508›Full record

ReviewAlcoholism, clinical and experimental research2022

Alcohol use disorder as a potential risk factor for COVID-19 severity: A narrative review.

Christopher B Forsyth, Robin M Voigt, Garth R Swanson, Faraz Bishehsari, Maliha Shaikh, Lijuan Zhang, Phillip Engen, Ali Keshavarzian

Open access · greenAbstract readReview
In one paragraph

Review in Alcoholism, clinical and experimental research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Alcohol's Effects on the Lung and Lung Disease.Alcohol research : current reviews · 2025
    Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Christopher B ForsythDepartment of Internal Medicine, Section of Gastroenterology, Rush University Medical Center, Chicago, Illinois, USA.ORCID 0000-0003-4690-7751
Robin M VoigtDepartment of Internal Medicine, Section of Gastroenterology, Rush University Medical Center, Chicago, Illinois, USA.ORCID 0000-0002-8010-0786
Garth R SwansonDepartment of Internal Medicine, Section of Gastroenterology, Rush University Medical Center, Chicago, Illinois, USA.
Faraz BishehsariDepartment of Internal Medicine, Section of Gastroenterology, Rush University Medical Center, Chicago, Illinois, USA.ORCID 0000-0001-5644-2586
Maliha ShaikhRush Center for Integrated Microbiome and Chronobiology Research, Rush University Medical Center, Chicago, Illinois, USA.
Lijuan ZhangRush Center for Integrated Microbiome and Chronobiology Research, Rush University Medical Center, Chicago, Illinois, USA.
Phillip EngenRush Center for Integrated Microbiome and Chronobiology Research, Rush University Medical Center, Chicago, Illinois, USA.
Ali KeshavarzianDepartment of Internal Medicine, Section of Gastroenterology, Rush University Medical Center, Chicago, Illinois, USA.ORCID 0000-0002-7969-3369
Rush University Medical Center · US

Funding

Center for Circadian Rhythms and Alcohol-Induced Tissue DamageR24AA026801 · NIAAA · RUSH UNIVERSITY MEDICAL CENTER · PI ALI KESHAVARZIAN · 2019 to 2026
$4.5M
Role of Alcohol and Circadian Disruption in Inflammation and Colon CancerR01AA023417 · NIAAA · RUSH UNIVERSITY MEDICAL CENTER · PI KESHAVARZIAN, ALI, KHAZAIE, KHASHAYARSHA · 2014 to 2018
$2.0M
Abnormal Food Timing and Circadian Dyssynchrony in Alcohol Induced Colon CarcinogenesisK23AA025387 · NIAAA · RUSH UNIVERSITY MEDICAL CENTER · PI BISHEHSARI, FARAZ · 2018 to 2022
$945k
Microbiota-Mediated Bidirectional Interactions Between Alcohol Misuse and Post-COVID-19 SyndromeR01AA029859 · NIAAA · RUSH UNIVERSITY MEDICAL CENTER · PI ABDEL MOHSEN, MOHAMED, KESHAVARZIAN, ALI · 2021 to 2023
$632k
NIAAA NIH HHS K23 AA025387NIAAA NIH HHS R01 AA023417NIAAA NIH HHS R01 AA029859NIAAA NIH HHS R24 AA026801
6 · The paper itself

Abstract

In Dec. 2019-January 2020, a pneumonia illness originating in Wuhan, China, designated as coronavirus disease 2019 (COVID-19) was shown to be caused by a novel RNA coronavirus designated as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). People with advanced age, male sex, and/or underlying health conditions (obesity, type 2 diabetes, cardiovascular disease, hypertension, chronic kidney disease, and chronic lung disease) are especially vulnerable to severe COVID-19 symptoms and death. These risk factors impact the immune system and are also associated with poor health, chronic illness, and shortened longevity. However, a large percent of patients without these known risk factors also develops severe COVID-19 disease that can result in death. Thus, there must exist risk factors that promote exaggerated inflammatory and immune response to the SARS-CoV-2 virus leading to death. One such risk factor may be alcohol misuse and alcohol use disorder because these can exacerbate viral lung infections like SARS, influenza, and pneumonia. Thus, it is highly plausible that alcohol misuse is a risk factor for either increased infection rate when individuals are exposed to SARS-CoV-2 virus and/or more severe COVID-19 in infected patients. Alcohol use is a well-known risk factor for lung diseases and ARDS in SARS patients. We propose that alcohol has three key pathogenic elements in common with other COVID-19 severity risk factors: namely, inflammatory microbiota dysbiosis, leaky gut, and systemic activation of the NLRP3 inflammasome. We also propose that these three elements represent targets for therapy for severe COVID-19.

Indexed as

AlcoholismCOVID-19Diabetes Mellitus, Type 2EthanolHumansMaleRisk FactorsSARS-CoV-2Ethanolalcohol use disorderCOVID-19dysbiosisLeaky gutNLRP3

Identifiers

PMID36394508
PMCPMC9722573
OpenAlexW4309244408

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.